ClinicalTrials.gg
RecruitingNCT07704164COLCOHIVUpdated Jul 15, 2026

Colchicine to Reduce Coronary Artery Inflammation in People With HIV

A Phase 2 interventional study of Colchicine 0.5 mg and Placebo in HIV Infection and Cardiovascular Diseases (CVD), sponsored by Instituto de Investigación Hospital Universitario La Paz. Recruiting at 4 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Instituto de Investigación Hospital Universitario La Paz · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 262 studies in HIV Infections with a site in Spain — 11 open to participants now, 21 under way, 8 of them phase 3. HIV Infections · Spain.

Planned enrollment
117th of 230
90 · median 100
Started
2026
with 2 others
Phase 2
39 of 262
2 open now
Primary completion
2028-12
later than 18 of 20 live
Registered
262nd of 262
by date

Among the 262 studies in HIV Infections with a site in Spain, this one is the 117th largest by planned enrollment of the 230 interventional ones that give a count, is one of 3 that started in 2026, is one of 39 in phase 2, reaches primary completion later than 18 of the 20 other live ones, and was the 262nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

11 of the 262 studies in HIV Infections with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in HIV Infections with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clinical trial. Neither participants nor researchers will know which treatment is assigned during the study. The primary endpoint is the change in coronary artery inflammation measured by coronary computed tomography angiography (CCTA) after 96 weeks.

Read the detailed description

Despite advances in antiretroviral therapy, people living with HIV (PWH) have an increased risk of cardiovascular disease compared with the general population. Persistent inflammation and immune activation are considered important contributors to accelerated atherosclerosis and coronary artery disease in this population. Coronary inflammation is associated with cardiovascular risk, but strategies targeting this mechanism in PWH remain limited.

Colchicine is an anti-inflammatory drug that has demonstrated cardiovascular benefits in patients with coronary artery disease by reducing inflammatory pathways involved in atherosclerosis. However, the effect of colchicine on coronary artery inflammation in PWH has not been previously evaluated. The hypothesis of this study is that colchicine may reduce coronary artery inflammation in PWH with high cardiovascular risk.

This phase II, randomized, double-blind, multicenter, placebo-controlled trial will include approximately 90 participants who will receive colchicine or placebo for 96 weeks. Changes in coronary artery inflammation will be assessed using coronary computed tomography angiography (CCTA) and the perivascular fat attenuation index (FAI), a non-invasive imaging biomarker of vascular inflammation. The study will also evaluate safety and changes in cardiovascular and inflammatory markers during follow-up.

03

Conditions studied

  • HIV Infection
  • Cardiovascular Diseases (CVD)

Keywords

  • Coronary artery inflammation
  • Atherosclerosis
  • Coronary computed tomography angiography
  • Fat attenuation index
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PWH > 50 years old
  • High cardiovascular risk measured by SCORE-2 > 5%
  • Stable antiretroviral therapy (ART) in the previous six months
  • Viral load \< 50 copies/mililiter for at least 1 year. One blip is allowed (Viral load between 20-200 copies/mililiter with a previous and after viral load determinations \< 20 copies per mililiter.
  • > 350 cells/mm3
  • Stable dose of an intermediate or high intensity statin in the previous year (statin dose should not be modified throghout the study unless there is a robust clinical indication). In case the participant does not receive statins, all other hypolipemiants (bempedoic acid, ezetimibe) will need to be at a stable dose as well in the previous year.
  • No clinical indication for a change in treatment based on European Society of Cardiology Guidelines
  • Written obtained according to international guidelines and local laws
  • Ability to understand the nature of the trial and the trial related procedures and to comply with them

Exclusion criteria

Exclusion Criteria:

  • Severe Heart failure defined as \< 35%.
  • Previous MI, stroke or coronary by-pass surgery
  • History of non-cutaneus prior to enrollment
  • History of inflammatory bowel disease or chronic diarrhoea
  • Renal dysfunctions defined as \< 50 ml/min or serum creatinine levels > 1.7 mg/dL
  • Severe hepatic impairments defined as a category C
  • Participants with stomach ulcers or gastrointestinal bleeding
  • Levels of over five times the OR levels of ALT over three times the upper limit of normal AND bilirrubin levels over one point five times the upper limit of normal
  • Participant is receiving drugs that inhibit the (e.g. Verapamil, Azithromycin, Clarithromycin, protease inhibitors, cobicistat), CYP2D6 or inhibitors of P-glycoprotein (see section 6.3.2 for more information)
  • Participant needs treatment with colchicine for any indication
  • Participants with highly elevated hsCRP > 10 mg/dL at screening
  • Women of . For this trial, definitions of nonchildbearing potential includes:
  • Permanent sterilisation methods including hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  • state, defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
  • Male participants are considered fertile after puberty unless permanently sterile by bilateral orchiectomy. To prevent pregnancies in female partners of male participants, they must agree to use highly effective contraceptive methods or have practiced sexual abstinence during the treatment period and until the end of relevant systemic exposure, defined as 5 half-lives of the IMP (9 days approximately).
  • Known to the active substances or any of the
  • Known iodine contrast allergy with prior history of anaphylaxis
  • Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Study Group

    Colchicine 0.5 mg orally once daily for 96 weeks.

    Drug: Colchicine 0.5 mg

  • Placebo comparator
    Control Group

    Matching placebo orally once daily for 96 weeks.

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.5 mg administered orally once daily for 96 weeks as an anti-inflammatory treatment to reduce coronary artery inflammation in people living with HIV and high cardiovascular risk.

  • DrugPlacebo

    Matching placebo administered orally once daily for 96 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in coronary artery inflammation

    Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the three main coronary arteries (right coronary artery \[RCA\], left anterior descending artery \[LAD\], and left circumflex artery \[LCX\]). The mean FAI score will be calculated as the average of analyzable FAI scores with valid baseline and post-baseline measurements across the three coronary arteries.

    Time frame: Baseline to Week 96

Secondary outcomes

  1. Changes in coronary plaque volume

    Change from baseline in total coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  2. Changes in coronary plaque burden

    Change from baseline in coronary plaque burden assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  3. Change in non-calcified plaque volume

    Change from baseline in non-calcified coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  4. Change in mixed plaque volume

    Change from baseline in mixed coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  5. Change in calcified plaque volume

    Change from baseline in calcified coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  6. Change in prevalence of positive remodeling plaques

    Change from baseline in the percentage of coronary plaques presenting positive remodeling assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  7. Change in prevalence of spotty calcium plaques

    Change from baseline in the percentage of coronary plaques presenting spotty calcium assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  8. Change in prevalence of napkin-ring sign plaques

    Change from baseline in the percentage of coronary plaques presenting a napkin-ring sign assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  9. Change in prevalence of low attenuation plaques

    Change from baseline in the percentage of coronary plaques presenting low attenuation characteristics assessed by coronary computed tomography angiography (CCTA) at Week 96.

    Time frame: Baseline to Week 96

  10. Change in serum hsCRP concentration

    Change from baseline in serum high-sensitivity C-reactive protein (hsCRP) concentration at Week 96.

    Time frame: Baseline to Week 96

  11. Change in serum IL-6 concentration

    Change from baseline in serum interleukin-6 (IL-6) concentration at Week 96.

    Time frame: Baseline to Week 96

  12. Change in serum IL-1β concentration

    Change from baseline in serum interleukin-1 beta (IL-1β) concentration at Week 96.

    Time frame: Baseline to Week 96

  13. Change in serum IL-18 concentration

    Change from baseline in serum interleukin-18 (IL-18) concentration at Week 96.

    Time frame: Baseline to Week 96

  14. Change in serum SuPAR concentration

    Change from baseline in soluble urokinase plasminogen activator receptor (SuPAR) concentration at Week 96.

    Time frame: Baseline to Week 96

  15. Change in extracellular vesicle NLRP3 levels

    Change from baseline in NLRP3 levels in extracellular vesicles at Week 96.

    Time frame: Baseline to Week 96

  16. Change in extracellular vesicle ASC levels

    Change from baseline in ASC levels in extracellular vesicles at Week 96.

    Time frame: Baseline to Week 96

  17. Change in extracellular vesicle Caspase-1 levels

    Change from baseline in Caspase-1 levels in extracellular vesicles at Week 96.

    Time frame: Baseline to Week 96

  18. Change in classical monocyte proportion

    Change from baseline in the proportion of classical monocytes (CD14++CD16-) at Week 96.

    Time frame: Baseline to Week 96

  19. Change in intermediate monocyte proportion

    Change from baseline in the proportion of intermediate monocytes (CD14+CD16+) at Week 96.

    Time frame: Baseline to Week 96

  20. Change in non-classical monocyte proportion

    Change from baseline in the proportion of non-classical monocytes (CD14++CD16++) at Week 96.

    Time frame: Baseline to Week 96

  21. Changes in leukocyte count

    Percentage change of leukocyte count in week 96

    Time frame: Baseline to Week 96

  22. Changes in arterial inflammation in individual coronary vessels measured by Fat Attenuation Index (FAI)

    Change from baseline in FAI and FAI score, including mean absolute change and mean percent change, assessed in individual coronary vessels (right coronary artery \[RCA\], left anterior descending artery \[LAD\], and left circumflex artery \[LCX\]).

    Time frame: Baseline to Week 96

  23. Mean arterial inflammation across analyzable coronary vessels measured by Fat Attenuation Index (FAI)

    Mean absolute change from baseline in mean FAI and FAI score calculated as the average of analyzable coronary vessels with valid baseline and post-baseline measurements.

    Time frame: Baseline to Week 96

  24. Adverse events and serious adverse events

    Incidence of solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs) during the study.

    Time frame: Over the whole period of patient study participation

Other outcomes

  1. Sex-related differences in inflammatory patterns and treatment response

    Difference in the percentage change of Fat Attenuation Index (FAI) between males and females in both treatment groups assessed by coronary computed tomography angiography (CCTA) in week 96.

    Time frame: Baseline to Week 96

  2. CYP2D6 genotype-related differences in treatment response

    Difference in FAI percentage change according to CYP2D6 metabolizer classification in participants receiving colchicine.

    Time frame: Baseline to Week 96

  3. Major adverse cardiovascular events (MACE)

    Difference in major adverse cardiovascular events (MACE) between colchicine and placebo groups assessed clinically in week 96.

    Time frame: Baseline to Week 96

  4. Cardiovascular risk score

    Change from baseline in the CaRi-Heart risk score, including mean absolute change and mean percentage change.

    Time frame: Baseline to Week 96

07

Study locations

2 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2028, 30 months later.

Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 30 months is below that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 15, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07704164
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Jul 15, 2026

Study contacts

José Ignacio Bernardino de la Serna, MD, PhD
Contact
Jose.bernardino@salud.madrid.org
(+34) 915683515
José Ignacio Bernardino de la Serna, MD, PhD
principal investigator · Hospital Universitario La Paz. IdiPAZ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion